

Title (en)  
THE USE OF 5 FLUOROURCIL, DELIVERED BY INOTOPHORESIS AS AN INHIBITOR OF CELL PROLIFERATION IN THE EYE, BULBAR AND PALPEBRAL CONJUNCTIVA, EYELID, PERI-ORBITAL SOFT TISSUES AND SKIN

Title (de)  
VERWENDUNG VON 5-FLUOROURACIL, VERABREICHT DURCH INOTOPHORESE, ALS HEMMER DER ZELLPROLIFERATION IM AUGE, DER BULBÄREN UND PALPEBRALEN KONJUNKTIVA, DEM AUGENLID, DEM PERIORBITALEN GEWEBEN UND DER HAUT

Title (fr)  
UTILISATION DE 5 FLUOROURCIL, ADMINISTRE PAR IONTOPHORESE EN TANT QU'INHIBITEUR DE LA PROLIFERATION CELLULAIRE DANS L'OEIL, LA CONJONCTIVE BULBAIRE ET PALPEBRALE, LA PAUPIERE, LES TISSUS MOUS ET LA PEAU PERIORBITAIRES

Publication  
**EP 1418919 A4 20070613 (EN)**

Application  
**EP 02747054 A 20020719**

Priority  
• US 0222860 W 20020719  
• US 30678801 P 20010720

Abstract (en)  
[origin: WO03007798A2] A method for treating neoplastic, angiogenic, fibroblastic, and/or immunosuppressive ocular irregularities of a living subject, comprising the steps of: providing a living subject, wherein the living subject includes an affected ocular area having a neoplastic angiogenic, fibroblastic, and/or immunosuppressive irregularity; providing a 5' fluorouracil based medicament, wherein the 5' fluorouracil based medicament is capable of inhibiting DNA synthesis; associating a therapeutically effective concentration of the 5' fluorouracil based medicament with the affected ocular area of the living subject; and decreasing the neoplastic, angiogenic, fibroblastic, and/or immunosuppressive ocular irregularity of the living subject.

IPC 8 full level  
**A61K 31/513** (2006.01); **C07D 239/553** (2006.01); **A61K 9/08** (2006.01); **A61N 1/30** (2006.01); **A61P 27/02** (2006.01); **A61P 35/00** (2006.01)

CPC (source: EP)  
**A61K 31/513** (2013.01); **A61N 1/30** (2013.01); **A61P 27/02** (2017.12); **A61P 35/00** (2017.12)

Citation (search report)  
• [XY] WO 9940967 A1 19990819 - HADASIT MED RES SERVICE [IL], et al  
• [X] WO 0051620 A1 20000908 - VITREO RETINAL TECHNOLOGIES IN [US]  
• [Y] EP 0927560 A1 19990707 - OPTISINVEST [AN]  
• [Y] US 5298017 A 19940329 - THEEUWES FELIX [US], et al  
• [Y] JP H0549702 A 19930302 - TEIJIN LTD  
• [PY] WO 0191853 A1 20011206 - BIOPHORETIC THERAPEUTIC SYSTEM [US]  
• [E] WO 03007961 A1 20030130 - IOMED INC [US], et al  
• See references of WO 03007798A2

Designated contracting state (EPC)  
DE FR GB IT

DOCDB simple family (publication)  
**WO 03007798 A2 20030130**; **WO 03007798 A3 20030619**; AU 2002316724 A1 20030303; EP 1418919 A2 20040519; EP 1418919 A4 20070613; JP 2004535462 A 20041125

DOCDB simple family (application)  
**US 0222860 W 20020719**; AU 2002316724 A 20020719; EP 02747054 A 20020719; JP 2003513412 A 20020719